https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-says-covid-vaccine-produced-immune-response-early-stage-trial-2023-01-06/
0
0
46 words
0
Comments
Germany's CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial.
You are the first to view
Create an account or login to join the discussion